Bioventus Looks to Regain Credibility With Investors

Bioventus reported 1Q23 orthopedic sales of $107.5 million, -0.7% compared to the first quarter of 2022.

After a challenging 2022, interim CEO Tony Bihl identified three focus areas to turn the company around: a strategic revenue of recent headwinds impacting the hyaluronic acid franchise, evaluating divesture options for non-core assets...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us